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Abstract 
Malignant melanoma patients with metastatic disease confined to the limbs or 
liver may be treated with hyperthermic isolated regional perfusion with a 
chemotherapeutic agent, most commonly melphalan. This procedure enables 
much higher tissue concentrations of the chemotherapeutic agent compared 
with systemic administration. Isolated limb perfusion (ILP) is approved for 
treatment of cutaneous metastatic melanoma, while the efficacy of isolated 
hepatic perfusion (IHP) is under evaluation for the treatment of liver 
metastases from uveal melanoma. Following ILP and IHP tumours often 
gradually decrease in size during a period of several months, which might be 
explained by a treatment-induced immunological anti-tumour response. This 
thesis aimed at investigating the potential role of the immune system for 
treatment response to ILP and IHP utilising in vivo analyses of patient 
material and mice models and in vitro cell cultures. As reported in Paper I 
and Paper II, patients who harboured a high fraction of activated and 
antigen-specific T cells in blood prior to ILP were more likely to achieve a 
complete disappearance of tumours following ILP. Furthermore, the in vitro 
and in vivo assays showed that melphalan exposure enhanced the activation 
of T cells and increased the numbers of intermediate and non-classical 
monocytes. This may be due to the melphalan-induced upregulation of 
immune-related stress markers on melanoma cells, which in turn stimulated 
immune cells. In Paper III it was reported that high levels of interferon-
stimulated gene products in patient blood, including CXCL10, CCL2 and 
PD-L2, were predictive of a favourable treatment response to ILP, and that 
the receptors of these ligands increased on immune cells following treatment.  
Paper IV describes different T cell immune profiles in blood between uveal 
melanoma patients and healthy controls, and showed that melanoma patients 
harboured a lower frequency of CD8+ T cells and more regulatory T cells. 
Uveal melanoma patients achieved a longer progression-free survival 
following IHP if they harboured a high fraction of activated T cells in blood. 
In conclusion, the findings presented in this thesis point towards a role of the 
immune system for treatment responses following both ILP and IHP, 
suggesting that it may be beneficial to combine isolated regional perfusion 
with immunotherapy.  
Keywords: Melanoma, isolated regional perfusion, ILP, IHP, melphalan, 
immunogenic cell death, T cells, monocytes, ISG  
Sammanfattning på svenska 
Malignt melanom är en av de vanligaste formerna av cancer i Sverige. Över 
90% av alla fall av melanom i västvärlden är i form av hudcancer, men 
melanom kan även uppstå på andra ställen i kroppen, exempelvis i ögonen. 
De flesta som drabbas av hudmelanom botas lätt genom kirurgiskt 
avlägsnande av tumören, men i de fall då metastaser, dvs. dottertumörer, 
uppstår blir behandlingen mycket svårare och prognosen värre. För 
ögonmelanom är metastasering ett stort problem då majoriteten av alla som 
drabbas av ögonmelanom utvecklar dottertumörer, vilket inte är fallet för 
hudmelanom. En behandlingsform för melanompatienter med metastaser 
isolerade till ett område av kroppen, framförallt till extremiter vid 
hudmelanom eller i lever för ögonmelanom, är hyperterm isolerad regional 
perfusion med cellgiftet melfalan. Under en perfusionsbehandling kopplas 
den drabbade kroppsdelens blodkärl till en hjärt-lungmaskin för att skapa ett 
separat, isolerat cirkulationssystem som är skilt från kroppens systemiska 
blodcirkulation. Till blodet i den isolerade kroppsdelen tillsätts höga doser av 
cellgift för att cirkulera runt under en timme, innan cellgiftet sköljs bort och 
kroppsdelen återigen kopplas till den systemiska cirkulationen. Detta upplägg 
gör det möjligt att enbart behandla den del av kroppen som är drabbad av 
tumörer, vilket minskar risken för generella biverkningar. Vissa av de 
tumörer som försvinner efter behandlingen minskar gradvis i storlek under 
flera månader innan de slutligen försvinner helt och hållet. En hypotes är att 
det beror på att perfusionsbehandlingen med melfalan aktiverar kroppens 
immunförsvar till att attackera de tumörer som överlever själva cellgiftet. 
Syftet med denna doktorsavhandling var att undersöka om immunförsvaret 
har en roll för behandlingsresponsen vid perfusion. Med hjälp av analyser av 
blod från perfusionspatienter, cellkulturer och försöksdjur har vi kunnat visa 
att melanompatienter med en stor andel aktiverade T-celler, immunceller 
viktiga vid försvar mot cancer och virus, innan perfusion svarar bättre på 
behandlingen. Perfusionsbehandlingen leder även till en högre aktivitetsgrad 
av T-cellerna och en högre produktion av de signalsubstanser som används 
för att locka T-celler och andra immunceller till tumörer. Detta kan bero på 
att melfalan påverkar de överlevande melanomcellerna så att de börjar visa 
upp och producera proteiner som aktiverar och lockar till sig immunceller. 
Fynden som presenteras i denna avhandling tyder på att det kan vara 
fördelaktigt att kombinera isolerad regional perfusion med 
immunstimulerande behandling för att få en ökad behandlingseffekt. 
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1. Background 
To find a solution to a problem, you must first define the problem. To find a 
treatment to cancer, you must first know what cancer is. 
1.1. Cancer 
Cancer is an umbrella term for a variety of diseases that all originate from 
cells with uncontrolled growth and which spread and invade other parts of the 
body. Often the cells will conglomerate in a mass known as a tumour. There 
are both benign and malignant tumours, wherein benign tumours do not 
invade nearby tissues or metastasise, e.g. spread, to other parts of the body, in 
contrast to malignant tumours. Malignant tumours are thus cancers. 
Depending on cell type and which tissue or organ the cells reside in, different 
types of cancer arise. 
Cell growth is heavily regulated. In order to maintain a functional 
multicellular organism each cell needs to function in its proper way, for 
example only dividing when needed and when ordered to. Cancer cells lack 
or have circumvented these regulatory mechanisms, causing them to have 
abnormal growth. This is due to an accumulation of mutations which causes 
genetic instability of the cells [1]. It is often considered that a tumour 
originates from a single abnormal cell, which produces daughter cells that in 
each generation accumulate more and more mutations due to natural 
selection.  
Genetic instability is of paramount importance in the transformation of a 
healthy cell to a cancer cell. It lays the foundation for eight underlying 
principles, the “hallmarks of cancer”, in cancerogenesis: self-sufficiency in 
growth signals (cancer cells develop their own signalling molecules that tell 
them to grow), insensitivity to anti-growth signals (cancer cells ignore signals 
that tell them to stop growing), evasion of apoptosis (evasion of self-
destruction), sustained angiogenesis (maintaining a constant blood supply), 
limitless replicative potential (limitless amount of cell divisions), tissue 
invasion and metastasis (spreading to other tissues and organs), deregulating 
cellular energetics (altered energy metabolism), and avoiding immune 
destruction (avoiding destruction by the immune system) [2, 3]. The latter is 
of interest since another enabling characteristic for the hallmarks, in addition 
to genetic instability, is inflammation induced and promoted by the tumour 
itself [3]. Thus, cancer cells might promote one type of immunologic 
response and at the same time manage to avoid destruction by immune cells. 
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1.1.1. Malignant melanoma 
Melanoma is cancer of the melanocytes, which are cells producing the 
pigment melanin. Melanocytes are originally derived from a structure called 
the neural crest; a transient group of cells found during the early stages of the 
development of an embryo [4]. The neural crest is a group of cells that are 
part of the early structure of the pre-cursor to the central nervous system 
(brain and spinal cord), the neural tube, but are pinched off during the 
formation of the tube and differentiate into cells that do not remain part of the 
central nervous system. Melanocytes are found throughout different parts of 
the body, such as in the skin, the eye and in mucosal membranes in the nasal 
cavity [5], the genital and urinary tract [6], and in the rectum [7].  
Melanin protects the epidermis (the upper most layer of the skin) from 
harmful ultraviolet (UV) light through absorbance and scattering of the 
radiation [8]. Except for producing melanin, melanocytes have other 
functions as well, such as by interacting with and regulating the immune 
system [9, 10]. This may in part explain why melanocytes reside in parts of 
the body that do not need protection against sun-derived UV damage. 
Depending on where in the body the melanocytes reside, different forms of 
melanoma arise. Despite originating from the same cell type, they differ in 
their genetic and phenotypic composition and how the disease develops in the 
patient. This thesis if focused on melanoma in the skin (cutaneous melanoma, 
Papers I-III), and in the eye (uveal melanoma, Paper IV). 
1.1.1.1. Cutaneous melanoma 
When discussing skin cancer, care should be taken to define what type of 
skin cancer that is the focus of discussion. Although all forms of skin cancer 
have some things in common, such as arising in the skin and being induced 
by UV radiation, there are big differences in incidence and mortality rates 
between them. In general there are three different types of cancers that are 
included in the term skin cancer; basal cell carcinoma, squamous cell 
carcinoma and cutaneous melanoma [11]. The incidence rates of basal cell 
carcinoma and squamous cell carcinoma are higher than for melanoma, 
though cutaneous melanoma has a higher mortality rate [12]. 
1.1.1.1.1 Epidemiology and causes 
Cutaneous melanoma is most common in countries with a predominantly 
Caucasian population, such as in Europe, Northern America and in Oceania 
[13]. In 2017 it was the fifth most common type of cancer among women and 
the sixth most common among men in Sweden, and unfortunately the 
incidence rate is steadily increasing [14]. Most melanoma patients in Sweden 
are diagnosed when they are around 60 years old, and the most common site 
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for the primary tumour is the extremities for women while it is the trunk for 
men [15-18]. 
Exposure to UV radiation is a known risk factor for the probability to 
develop cutaneous melanoma. In WHO’s list of different agents and their 
carcinogenic hazards to humans, UV radiation is found in group 1, where 
chemicals and other agents who have been shown to be carcinogenic belong 
[19]. For a reference, tobacco smoke and plutonium are also in group 1. The 
hazardous property of UV radiation is that it damages DNA.  
Studies have shown that the risk of developing melanoma is highest during 
intermittent sun exposure compared to chronic sun exposure [20]. Severe 
sunburns and high sun exposure during childhood are also risk factors. The 
UV radiation which is derived from the sun fall into three categories: UVA 
(315-400 nm), UVB (280-315 nm) and UVC (100-280 nm). UVC is absorbed 
by the ozone layer and does not affect humans, while UVB penetrates only 
the uppermost layer of the skin (epidermis) and UVA reached down to the 
middle layer (dermis). UVB causes direct DNA damage by absorption into 
the DNA molecule where it induces molecular rearrangements while UVA 
causes indirect DNA damage by the formation of reactive oxygen species 
[21].  
As for many other types of cancer, mutations in certain genes have been 
correlated to a higher risk of developing melanoma. Examples of such genes 
are the tumour suppressor genes CDKN2A and BAP1, and the oncogene 
CDK4 [22, 23]. Another interesting gene where a mutated status has been 
linked to melanoma is MC1R. MC1R encodes for the melanocortin-1-receptor 
which regulates both hair and skin pigmentation in humans. People with red 
hair and fair skin often have mutated variants of the MC1R gene [24], and 
these features together with a high number of common and atypical naevi 
(i.e. moles) have been linked to a higher risk of developing melanoma [25].  
1.1.1.1.2 Subtypes and staging 
Cutaneous melanoma is clinically classified into four different subtypes 
depending on how and where the tumour grows [25]. The most common type 
is superficial spreading melanoma, accounting for approximately 60% of all 
cases in Sweden [15, 17, 18], which has a horizontal growth pattern in 
contrast to nodular melanoma which almost exclusively has a vertical growth. 
Nodular melanoma accounts for 20% of the Swedish cutaneous melanoma 
cases [15, 17, 18]. Acral lentiginous melanoma can be found on e.g. the 
fingers, the palm of the hand and the sole of the foot (acral meaning affecting 
or belonging to peripheral body parts), and is uncommon among Caucasian 
patients but is percental more common among patients of African, Asian and 
Hispanic descent. Lentigo maligna melanoma is correlated with long-term 
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UV exposure and increasing age and can grow down into the hair follicles of 
the skin.  
To classify the spread of the disease, melanoma is categorized into different 
stages according to the TNM staging system [26]. T defines the depth of the 
primary tumour and if the primary tumour has ulceration, N explains the 
spread to nearby lymph nodes and M contains information about distant 
metastasis and is defined according to anatomical site. Based on the TNM-
status the patient is then staged into a numerical staging system from stage 0 
to stage IV, where the higher the number the more the metastatic spread. 
Stage 0 is superficial and non-invasive, stage I and II is melanoma without 
sign of metastatic spread, stage III indicates metastasis to lymph nodes and 
stage IV is when the disease has distant metastasis and thus has spread to 
other organs. Two other measurements that are sometimes utilised for 
melanoma is the Breslow thickness (describing the vertical thickness of the 
primary tumour) and the Clark level (how far down into the skin the primary 
tumour has invaded) [26]. 
1.1.1.1.3 Prognosis and treatment 
The prognosis for cutaneous melanoma 
depends a lot on the characteristics of the 
tumour at the time of diagnosis and the state of 
metastasis. The melanoma-specific and overall 
survival decreases rapidly with increasing 
depth of the primary tumour and a higher 
degree of metastatic spread [15-18]. Among 
Swedish melanoma patients diagnosed with 
stage I and stage II melanoma, 90% are alive 
after five years without dying of their disease. 
For stage III patients, the corresponding 
percentage is 36% and for stage IV it is 25% 
[17]. Worth noticing is that over 90% of all 
patients are diagnosed with stage I or stage II [16, 17].  
The standard treatment option for patients with stage I or II melanoma 
without metastatic spread to lymph nodes is surgical excision of the tumour. 
To prevent recurrence of the tumour a certain area around it is also often 
removed; the margin of the excision is based on the thickness of the tumour. 
In case of suspicion of metastatic spread to lymph nodes, which is usually the 
first place of metastasis, a sentinel lymph node biopsy may be performed. 
The sentinel lymph node is the first draining lymph node from the primary 
tumour and is hypothetically the first lymph node metastases gather in. The 
sentinel lymph node can be found by injecting a radioactive tracer or a dye 
A short primer on survival: 
 
• Overall survival (OS): Time 
from diagnosis until death of 
any cause. 
• Melanoma-specific survival: 
Time from diagnosis until 
death due to melanoma. 
• Progression-free survival 
(PFS): Time from start of 
treatment until progression 
and/or recurrence of 
melanoma. 
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near the primary tumour and then surgically remove the nodes that have 
taken up the radioactive tracer or the dye. By removing and examining the 
lymph node it is possible to evaluate the metastatic spread of the disease [27-
29]. 
For patients with metastatic disease, surgery is usually not curative but can be 
utilised to prolong and improve the life of the patient. Depending on how 
many metastases and where they are located, patients may or may not benefit 
from surgical excision of their metastatic tumours [30]. Other treatment 
strategies that may be employed are targeted therapies, locoregional therapies 
and immunotherapies.  
In addition to harbouring mutated versions of CDKN2A, BAP1 and CDK4, 
40-60% of all melanoma patients do also have a changed version of BRAF 
[31-33]. BRAF encodes for the protein B-raf which is a part of the 
MAPK/ERK pathway; a signal-transduction pathway wherein signalling 
molecules bind to a receptor on the cell surface and induce an intracellular 
signalling cascade, ultimately regulating vital cell functions such as cell 
growth and proliferation. The mutated BRAF common in melanoma encodes 
for a version of the protein that is highly activated [31]. Another component 
of the MAPK/ERK pathways is N-ras, encoded by the NRAS gene. It is also 
frequently mutated in melanoma, with 15-20% of all melanomas harbouring a 
mutated variant [32, 33]. Targeted therapies have been developed wherein 
inhibitors target the most common mutated variant of the BRAF gene product 
or other proteins in the same signalling pathway. Despite a relatively high 
response rate, many patients will experience progression of their disease 
since it is common to develop resistance to the inhibitors [34]. 
For in-transit melanomas, i.e. when the melanoma has started to metastasise 
and spread from the primary tumour via the lymph vessels but have not yet 
reached the nearest lymph nodes, locoregional therapies may be an option. 
Locoregional therapies only treat the part of the body affected by metastatic 
disease, compared to systemic therapies which affect the whole body. Two 
locoregional treatment options are isolated regional infusion and isolated 
regional perfusion with chemotherapeutic agents, the latter being the subject 
of this thesis and will be described in detail in chapter 1.2. 
Immunotherapy has during recent years been an important part in the 
treatment of metastatic melanoma. Immunotherapy aims to boost the body’s 
own immune system to attack the cancer cells, which might be achieved by 
e.g. making cancer cells more attractive to immune cells or activating 
immune cells. Immunotherapy in the treatment of cancer will be discussed 
further in chapter 1.3. 
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1.1.1.2. Uveal melanoma 
Uveal melanoma arises in the uvea of the eye. The uvea consists of three 
parts; the iris which controls the size of the pupil and thus the amount of light 
entering the eye, the ciliary body which holds the lens and produces the fluid 
found between the cornea and the lens, and the choroid which is a vascular 
layer of the eye containing connective tissues and blood vessels. 
 
Figure 1. Schematic diagram of the human eye. The uvea consists of the iris, the ciliary body 
and the choroid. 
1.1.1.2.1 Epidemiology and causes 
Despite being a rather rare form of cancer, uveal melanoma is the most 
common intraocular tumour in adults and is the second most common form 
of melanoma after cutaneous melanoma. It constitutes approximately 5% of 
all melanoma cases [35, 36].  As with cutaneous melanoma, uveal melanoma 
is most common in Caucasian populations [37, 38], and in Sweden there are 
approximately 70 diagnosed uveal melanoma cases each year [12]. 
In contrast to cutaneous melanoma where exposure to UV radiation is a 
known risk factor for the development of the disease, the relationship 
between UV radiation and uveal melanoma is not as clear. Intermittent 
exposure to sun-derived UV light has not been shown to increase the risk of 
developing uveal melanoma [39], even though hypothetically melanocytes in 
the eye should be affected as well. It is known that people with fair skin and 
light eye colour, such as blue-eyed Caucasians, have a higher risk of 
developing uveal melanoma [40]. 
Mutations in the BAP1 gene have shown to increase the risk of the 
development of uveal melanoma [41-44]. Two other genes that have shown 
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to be implicated in the development of cutaneous melanoma, CDKN2A and 
CDK4, do not seem to increase the risk of uveal melanoma [45-48], 
indicating differences in the genetic landscape of the two forms of melanoma. 
1.1.1.2.2 Subtypes and staging 
The TNM staging system is also applicable for uveal melanoma and can be 
utilised to further categorise the spread of the disease in a numerical system 
with stages from I to IV [49, 50]. If the affected eye is removed or a biopsy is 
taken, the additional stage G might be added. G denotes the pathological 
appearance of the tumour, i.e. what the tumour cells and the tissue look like 
when observed with a microscope. Uveal melanoma tumours consist of cells 
that can be classified as spindle cells or epithelioid cells [51]. An extremely 
brief explanation of the difference between the two cell types is that spindle 
cells look more slender and stream-lined, while epithelioid cells are bulkier. 
1.1.1.2.3 Prognosis and treatment 
The problem with uveal melanoma is that the risk of developing metastatic 
disease is rather high. 25% of all uveal melanoma patients will have been 
diagnoses with metastatic disease after five years, and among them the 
majority will have developed metastases in the liver [52, 53]. Only 20% of all 
uveal melanoma patients will be alive one year after being diagnosed with 
metastatic disease, and after two years only 4-8% of all patients are alive [52, 
53]. 
It is not fully known why uveal melanoma has such a high metastasis rate to 
the liver. Uveal melanoma cells that form metastases travel through the 
circulatory system of the blood, in contrast to cutaneous melanoma cells that 
more often traffic the lymphatic system, which is due to the lack of 
lymphatics in the eye. But this does not explain why uveal melanoma cells 
end up in the liver, since there are other stops between the eyes and the liver 
if you travel via the blood road, such as the lungs. Thus, it is thought that the 
liver produces substances that attract and stimulate the growth of uveal 
melanoma cells [54]. For example, the liver produces high amounts of C-X-C 
motif chemokine 12 (CXCL12) which binds to the receptor C-X-C motif 
chemokine receptor 4 (CXCR4) on e.g. melanoma cells and recruits them to 
the liver.  
Genetic studies of primary uveal melanomas have shown that the loss of one 
copy of chromosome 3 is strongly correlated to a poor prognosis and higher 
risk of developing metastatic disease [55-57]. Inactivating mutations in the 
BAP1 gene usually occur together with loss of chromosome 3 [58]. It has 
recently been revealed that primary uveal melanomas can be further divided 
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into four genetically distinct subgroups with different prognoses; two groups 
with loss of one copy of chromosome 3 and two groups without loss [59]. 
The major treatment options for primary uveal melanoma are either removal 
of the eye (enucleation) or radiotherapy. Enucleation used to be the standard 
treatment, but it has been shown that there is no difference in survival 
between patients undergoing enucleation or more conservative treatments 
such as radiotherapy [60, 61], resulting in enucleation now being utilised 
only for big tumours where more conservative treatments will not be able to 
save the patient’s vision [62]. One commonly used type of radiotherapy is 
brachytherapy in which a sealed radiation source is placed next to the tumour. 
Other types of conservative therapies where the affected eye is not removed 
include photodynamic therapy, wherein light is used to induce the production 
of radicals and reactive oxygen species, and thermotherapy, wherein heat is 
used to treat the tumour [63]. 
Due to the high rate of liver metastasis formation, management of metastatic 
disease is of outmost importance. Unfortunately, no specific treatment option 
has of yet been proven successful in improving survival, despite many 
different types of therapies being developed and tested [64]. As for cutaneous 
melanoma, locoregional therapies, targeted therapies and immunotherapies 
have been tested in various studies. Worth noting is that BRAF mutations are 
not common in uveal melanoma, subsequently rendering B-raf inhibitors 
useless. Instead, in uveal melanoma mutations in the genes GNAQ and 
GNA11 are much more common, with over 90% of all primary tumours 
harbouring mutations in GNAQ or GNA11 [65]. Both genes encodes for 
proteins that are part of the intracellular IP3 pathway which regulates the 
release of calcium inside the cell. 
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1.2. Isolated regional perfusion 
Hyperthermic isolated regional perfusion with chemotherapeutic agents is a 
locoregional chemotherapy wherein the treatment only affects the part of the 
body where tumours are located. It is used for cancer patients with tumours 
confined to a body part or an organ, such as a limb or the liver. The main idea 
behind isolated regional perfusion is that it enables the administration of 
much higher concentrations of a chemotherapeutic drug compared to regular 
systemic chemotherapy; if the drug is only locally administered, systemic 
side effects and toxicity can be avoided.  
At the Sahlgrenska University Hospital in Gothenburg, the only centre in 
Sweden where isolated regional perfusion is performed, isolated limb 
perfusion (ILP) is utilised for cutaneous in-transit melanoma with metastatic 
disease confined to the limbs, while the usage of isolated hepatic perfusion 
(IHP) in the treatment of uveal melanoma liver metastases is currently being 
investigated in a randomised clinical trial. Melphalan is the most commonly 
used chemotherapeutic drug for ILP and IHP, and the procedure is conducted 
under mild hyperthermia (40oC). Patients with bulky disease or who has 
undergone repeated perfusions might also receive tumour necrosis factor α 
(TNF-α).  
1.2.1. The technique 
Isolated regional perfusion is an old method, first described and used already 
in the 1950’s [66]. Since then the method has been refined and adapted, and 
today it is used in the treatment of malignant melanoma and other type of 
solid cancers, such as soft-tissue sarcomas.  
A detailed description of the technical aspects of ILP and IHP is beyond the 
scope of this thesis but can be found elsewhere [67]. The main idea is to 
redirect the major blood flow to the limb or the liver by clamping the artery 
and veins, insert cannulas and connect the cannulas to a heart-lung machine, 
thus creating an isolated circulatory system. The blood that is perfused 
through the limb or the liver is oxygenated and supplied with high doses of 
the chemotherapeutic agent melphalan, and the treated tissue is held at a 
temperature of 40oC. Radioactive isotopes are added to the perfusate to 
enable monitoring of potential leakage to the systemic circulation. The total 
perfusion time is 60 minutes, followed by rinsing of the limb or the liver with 
a salt-based solution to get rid of the melphalan residues.  
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1.2.2. Treatment response  
Clinical response to the treatment regarding tumour burden is evaluated after 
three months according to WHO’s criteria as complete response (CR), partial 
response (PR), stable disease (SD) and progressive disease (PD) [68]. CR is 
defined as disappearance of all tumours, PR is a decrease of more than 50% 
of total tumour burden, PD is an increase of more than 25% in existing 
tumours or the appearance of new tumours, and SD is where none of the 
criteria for CR, PR or PD are met. ILP with melphalan has a CR rate of 50-
70%, with over 85% of all patients achieving an overall response (CR or PR) 
[69-71]. IHP with melphalan has a CR rate of 20%, with an overall response 
rate of 70% [72]. Five years after treatment around 30-40% of ILP patients 
will still be alive [69, 70], while the effectiveness of IHP in improving 
overall survival is currently being investigated in a clinical study. The 
SCANDIUM trial (ClinicalTrials.gov identifier number: NCT01785316) is a 
Figure 2. Schematic representation of the set-up for ILP. 
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clinical study evaluating if IHP improves overall survival compared to best 
alternative care for uveal melanoma patients with liver metastases [73].  
1.2.3. Melphalan 
Chemotherapy is the usage of chemical compounds which inhibit cell growth 
and induce cell death in the treatment of cancer. Chemotherapeutic agents 
were first used in cancer treatment around the time of World War II. During 
World War I mustard gas was effectively used as a chemical warfare agent, 
and during World War II there was continued interest in researching mustard 
gas. There was an academic interest in the cytotoxic properties of the gas, and 
the question arose whether or not it could also be used to kill cancer cells. 
The first time a derivative of mustard gas was intravenously used to treat 
cancer was in 1942, and the rest, as they say, is history [74-76]. 
Melphalan, also known as phenylalanine mustard, is a 
nitrogen mustard derived from mustard gas. It is an 
alkylating agent and adds an alkyl group to the guanine 
base of DNA, causing linkage between DNA strands and 
subsequently inhibition of DNA synthesis and cell 
death. Is it used for systemic treatment in multiple 
myeloma and ovarian cancer [77], but systemic 
administration of melphalan is not feasible for 
melanoma since the effective dose is higher than what 
the body tolerates [78]. Thus, melphalan is only 
administered with ILP or IHP in the treatment of 
malignant melanoma. 
1.2.4. Hyperthermia 
ILP and IHP with melphalan is often performed under mild hyperthermia 
(40oC). There are synergistic effects in play between hyperthermia and 
melphalan, resulting in enhanced death of the cancer cells [79-81]. There are 
many underlying factors behind the synergy, such as a higher uptake of 
melphalan in tumour tissue during hyperthermia [82] and an increase in the 
amount of DNA crosslinks produced by melphalan [79].  
Furthermore, hyperthermia has in itself anti-tumoural properties. In addition 
to the direct killing of cancer cells by heat, hyperthermia inhibits 
angiogenesis, thus preventing tumours from forming new blood vessels 
which are critical for their survival [83, 84]. Hyperthermia has also been 
indicated to induce anti-tumoural immune responses, as reviewed in [85, 86]. 
This is due to many different factors, for example the increased expression of 
heat-induced stress ligands, such as heat-shock proteins (HSPs), which bind 
Figure 3. Structural 
formula for melphalan. 
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to and activate immune cells such as dendritic cells (DCs) and natural killer 
(NK) cells. 
1.2.5. Tumour necrosis factor α  
Tumour necrosis factor α (TNF-α) is a cytokine, a cell signalling protein, and 
a major driver of the inflammatory response. It has a dual role in the context 
of cancer; it is anti-tumoural since it directly can kill cancer cells by 
triggering apoptosis (programmed cell death) in cancer cells, and it is pro-
tumoural due to activation of the transcription factor NF-κB and by 
sustaining an inflammatory tumour environment (remember, inflammation is 
one of the enabling characteristics for the hallmarks of cancer) [87-91].  
TNF-α is sometimes utilised in ILP and IHP due to its ability to enhance the 
uptake of melphalan into tumour cells by affecting the tumour vasculature 
and increasing the blood vessel permeability [92, 93]. It is most often utilised 
for patients requiring multiple perfusions or for patients with big and bulky 
tumours where uptake of melphalan might be limited due to the tumour size. 
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1.3. The immune system 
The immune system is the body’s own defence against disease. It protects us 
from foreign pathogens, such as bacteria and viruses, but does also provide 
protection against diseases arising from within the body itself, most notably 
against cancer. The immune system is very complex and comprises several 
levels of protection, from the small proteins of the complement system via 
immune cells to the skin and mucosa, which are our first and biggest barriers 
against invading pathogens.  
There is both innate and adaptive immunity. Briefly described, innate 
immunity is the part of the immune system which first reacts to an invading 
pathogen. It provides a swift response with broad specificity. In contrast, 
adaptive immunity is highly specific and contains immune cells which upon 
the first encounter with a pathogen develop a “memory” of the pathogen, 
prompting the cells to react much faster and stronger subsequent times the 
pathogen is encountered  [94].  
1.3.1. Immune cells 
The immune cells (white blood cells or leukocytes) are cells dedicated to 
protect the body and are found circulating in blood or stationed in tissues. All 
blood cells (immune cells, red blood cells and platelets) are produced in the 
bone marrow and are derived from the same hematopoietic stem cell. The 
stem cell forms immune cells of two different lineages; lymphoid cells and 
myeloid cells [94]. The cells have different functions and 
mature cells can be found in different parts of the body. 
Another common classification of immune cells purified 
from peripheral blood is into peripheral blood 
mononuclear cells (PBMCs) and polymorphonuclear 
leukocytes (PMNs). A very common way to separate 
immune cells from whole blood is by density gradient 
separation in which blood is placed on top of a 
hydrophilic polymer solution in a tube and then 
centrifuged. Due to differences in density between 
different cells, some cells will sediment through the 
polymer while others will not, creating a layered solution 
in the tube after centrifugation. The bottom layer 
contains red blood cells and PMNs, the layer above is 
the polymer, on top of the polymer is a thin layer with 
PBMCs and the uppermost layer contains plasma [95].   Figure 4. Diagram of 
density gradient separation 
of whole blood. 
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Table 1. Cheat sheet for different classifications of the most common immune cells found in 
blood. 
There are many different types of immune cells and many of them cooperate 
during an immunological response. Below follows descriptions of the three 
major immune cell populations of relevance for this thesis; dendritic cells, 
monocytes and T cell. 
1.3.1.1. Dendritic cells 
Dendritic cells (DCs) are of myeloid lineage and are found in blood in an 
immature form and in tissues and lymph nodes as more mature cells. They 
are relatively rare in blood and constitute <1% of all PBMCs [96-98]. DCs 
are professional antigen-presenting cells (APCs) and are thought to be 
required for activation of naïve T cells (see section 1.3.2 for more 
information about antigen presentation). They also secrete many cytokines 
which help to further stimulate an immune response. 
DCs are often classified into three different subtypes; plasmacytoid DCs, 
conventional CD1c+ DCs and conventional CD141+ DCs [99, 100]. The 
plasmacytoid DCs are excellent producers of cytokines, especially of type I 
and III interferons. Of note, type I interferons are of importance for the 
findings in Paper III. The conventional DCs are potent stimulators of T 
cells. CD1c+ DCs are more abundant than CD141+ DCs, and while both are 
good at stimulating CD4+ helper T cells, the CD141+ DCs are much better at 
cross-presenting antigens to cytotoxic CD8+ T cells. During inflammatory 
conditions or when cultured in vitro, DCs might also be derived from 
monocytes. 
 Lymphoid Myeloid Adaptive Innate PBMC PMN 
B cell X  X  X  
Basophil  X  X  X 
Dendritic 
cell (DC)  X  X X  
Eosinophil  X  X  X 
Monocyte  X  X X  
Neutrophil  X  X  X 
Natural killer 
(NK) cell X   X X  
T cell X  X  X  
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1.3.1.2. Monocytes and macrophages 
Monocytes do also belong to myeloid-lineage cells, and they share some 
similarities with DCs. They constitute approximately 10% of all immune 
cells in blood [101]. Monocytes are APCs and can during certain conditions 
be converted into DCs. They are also potent cytokine producers. 
Furthermore, when migrating into tissues they are transformed into 
macrophages; large immune cells which are stationed in tissues, patrolling 
the area looking for invading pathogens. Macrophages and monocytes are 
excellent phagocytes, meaning that they are cells capable of engulfing and 
subsequently destroying cells and structures detrimental to a healthy body, 
such as pathogens, cell debris and dead cells (macrophage actually means 
“big eater” in Greek). 
Monocytes are found in blood while macrophages are present in tissues. 
Monocytes are usually divided into three different subtypes based on the 
expression of the cell surface receptors CD14 and CD16 [101-103]. Classical 
monocytes (CD14++CD16-) are the most common type of monocyte, 
constituting around 80-90% of all monocytic cells, and often migrate into 
tissues to become macrophages. They can also convert into the intermediate 
(CD14++CD16+) and nonclassical (CD14+CD16++) monocytes which 
accumulate during infections and inflammatory conditions and produce high 
levels of the pro-inflammatory cytokines TNF-α and interleukin 1 β (IL-1β). 
The different monocyte populations are discussed in Paper I. 
The majority of tissue-resident macrophages are not descendants of 
monocytes, but are instead developed before birth from their own pre-cursor 
cells and are present throughout the whole adult life. During inflammatory 
conditions the pool of tissue-resident macrophages are maintained through 
the addition of monocyte-derived macrophages. Macrophages have different 
functions and different gene signatures depending on which tissue or organ 
they reside in, suggesting that they are highly adapted to their surrounding 
environment [104]. They are also given different names depending on tissue 
type, such as Kupffer cells in the liver, microglia in the brain and osteoclasts 
in bone. 
1.3.1.3. T cells 
T cells are lymphocytes essential for adaptive immunity. They activate and 
regulate various type of lymphocytes (including themselves), and are 
important in the eradication of cancer cells and virus-infected cells. The “T” 
in T cell stands for thymus. Like all other immune cells T cells are first 
developed in the bone marrow, but they mature and are transformed into 
functional T cells in the thymus. The fraction of T cells in peripheral blood 
during healthy conditions varies a lot between different individuals, but is 
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typically around 60-80% of all PBMCs. T cells are of importance for Papers 
I-IV in this thesis. 
There are two major T cell subpopulations; helper T cells and cytotoxic T 
cell. They are distinguished and denoted by the receptors CD4 for helper T 
cells and CD8 for cytotoxic T cells.  
1.3.1.3.1 CD4+ helper T cells 
CD4+ T cells are regulators of immunity; activating or inhibiting responses 
from e.g. CD8+ T cells and the antibody-producing B cells by receptor 
interactions and secretion of cytokines. The CD4+ T cells are further 
classified into different groups based on which cytokines they produce and 
which transcription factors that are responsible for the development of that 
particular CD4+ T cell subtype. Th1 cells produce interferon γ (IFN-γ) and 
interleukin 2 (IL-2) which activate CD8+ T cells and macrophages. They are 
important for the development of immune responses against intracellular 
pathogens. In contrast, Th2 cells mediate responses against extracellular 
pathogens by the production of e.g. interleukins 4 and 5 (IL-4, IL-5) which, 
among many things, activate B cells, basophils and eosinophils. Th17 cells 
primarily produce interleukin 17 (IL-17) which recruits and activates 
neutrophils to help in the eradication of extracellular bacteria and fungi. T 
regulatory cells (Tregs) are another member of the CD4+ T cell family. 
Compared to the other CD4+ T cells, Tregs have a different function; instead of 
activating an immune response, Tregs are responsible for suppressing it. Tregs 
are responsible for curbing the activity of other immune cells, particular other 
T cells, that otherwise would lead to damage; such as overreactive T cells or 
T cells that mount a response against healthy tissue, causing autoimmune 
disorders. This is done through many mechanisms, one is the secretion of 
immunosuppressive cytokines such as transforming growth factor β (TGF-β) 
and interleukin 10 (IL-10) [105, 106]. 
CD8+ cytotoxic T cells 
While CD4+ T cells regulate and facilitate the induction of an immune 
response, CD8+ T cells directly kills abnormal cells. After being activated 
What’s up with all the CDs? 
 
In immunology CD is an abbreviation for “cluster of differentiation” and not for a disc-
shaped storage device. It is basically a naming system for cell surface molecules used for 
identifying different types of cells. A CD structure is usually a receptor or a ligand found 
on the cell surface, and often their function and relevance to the cell is known. For 
example, all T cells express CD3, which is a co-receptor to the main T cell receptor which 
T cells need to recognise antigens. By combining different CD markers it is possible to 
identify different immune cells, e.g. a cell expressing both CD3 and CD4 but not CD8 
(written as CD3+CD4+CD8-) is a helper T cell. 
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and told which cell to target (via antigen-presentation by APCs), the CD8+ T 
cell kill the target cell through induction of apoptosis via the release of 
cytotoxic molecules or direct cell-to-cell contact. They contain and release 
perforin, which creates pores in the cell membrane of the target cell, and 
granzyme B, which enters the target cell through the pores and induces 
apoptosis. Alternatively, the structure Fas ligand (FasL) on the surface of 
activated CD8+ T cells can bind to the receptor Fas on the target cell. Upon 
binding the FasL/Fas complex triggers the activation of an intracellular 
signalling cascade, ultimately leading to apoptosis of the target cell [107]. 
1.3.2. Immune responses against pathogens 
What really happens during an infection or when the immune system mounts 
a response against cancer cells? Do the immune cells just circulate 
throughout the body and attack everything that seems suspicious? The truth is 
that the immune system is a highly complex and dynamic system, where 
different cells have different roles. The threats the immune cells need to 
recognise and eliminate are of widely different natures; from foreign bacteria 
and parasites, to virus that infiltrate the body’s own cells and to cancer cells 
which are altered host cells, meaning that different kinds of immune 
responses need to be initiated. One thing that is common for all immune 
responses is that they always include collaborations between different kinds 
of immune cells. 
1.3.2.1. Extracellular pathogens 
During an infection by foreign pathogens, e.g. bacteria, the bacteria are first 
recognised by innate immune cells patrolling the area which happened to be 
infected. Among the first responders are the tissue-resident macrophages that 
try to eliminate the pathogens by e.g. phagocytosis. Macrophages, and other 
myeloid cells, express pattern recognition receptors (PRR) on the cell surface 
which bind to certain patterns, or structures, found only on microbes, so 
called pathogen-associated molecular patterns (PAMPs). The stimulation of 
PRRs triggers the activation of transcription factors in the myeloid cells, 
which among other things leads to production and secretion of cytokines that 
regulate other parts of the immune system. One important group of cytokines 
are chemokines, which are proteins stimulating other cells to migrate to the 
area of infection. By following increasingly higher concentrations towards 
the source of the chemokine, immune cells stationed far from the site of 
infection can find their way to the pathogen. Innate myeloid cells, such as 
neutrophils, are abundant in blood but not in tissues. However, during an 
infection neutrophils rapidly respond and migrate to the area of infection and 
can rapidly start eliminating the pathogen [94]. In contrast to the myeloid 
cells, the activation and recruitment of T cells is much more complex. 
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Naïve T cells are mainly present in secondary lymphoid organs such as 
lymph nodes or the spleen (the primary lymphoid organs are the bone 
marrow and the thymus where immune cells are created and mature), waiting 
to be activated. An APC, for example a DC, needs to take up a part of the 
pathogen (the antigen), travel through the lymph vessels to the lymph node 
and present the antigen for the T cell. By presenting the antigen on cell 
surface structures called major histocompatibility complexes (MHC), the 
antigen becomes recognisable by the T cells. T cells have different T cell 
receptors (TCRs) that recognise different antigen-MHC complexes, and if a T 
cell with the correct TCR recognises the antigen in the context of MHC, the T 
cell becomes activated and starts to proliferate. This is a process called 
antigen-presentation. There are two kinds of MHC; class I and class II. All 
APCs express MHC class II and use it to present antigens to CD4+ T cells, 
while CD8+ T cells can only recognise antigens presented on MHC class I. 
After being activated towards its particular antigen for the first time, T cells 
differentiate into effector and memory T cells. The memory cells are long-
lived and will react rapidly the second time they encounter the same antigen, 
thus enabling them to mount a faster response [94].  
1.3.2.2. Viruses and cancer 
In contrast to the restricted expression of MHC class II, almost all cells in the 
body have MHC class I. This is because all cells need to be able to send a 
message to the immune system in case they become intracellularly infected, 
for example by viruses. By constantly sampling their own insides and 
presenting peptides on the MHC class I molecules, infected cells show 
circulating memory CD8+ T cells what is inside them. If the presented 
peptide is a “normal” peptide, the T cells will not interfere. But if the 
presented peptide is of foreign origin, e.g. virus-derived, and the CD8+ T cell 
has been pre-activated against this peptide by an APC, the CD8+ T cell will 
start to eradicate the infected target cell [94].  
While normally only intracellular peptides are presented on MHC class I, 
APCs can present both extracellular and intracellular antigens on MHC class 
I. In order for the naïve T cells, which have no memory functions, to 
recognise an intracellular antigen from a target cell for the first time, an APC 
must present the peptide (which for the APC is extracellular) on MHC class I 
to a naïve CD8+ T cell. DCs are the APCs that most effectively can do this 
kind of antigen-presentation, which are known as cross-presentation [94]. 
Cross-presentation is of importance for the eradication of tumours since 
cancer cells do not have any “foreign” antigens that may trigger an immune 
response.  
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Figure 5. Very simplified depiction of initiation and implementation of an anti-tumour 
response. 1) An APC, here a DC, takes up a tumour antigen (e.g. a DAMP) from a cancer cell 
and travels to the lymph node where 2) it cross-presents the antigen to a naïve tumour-specific 
CD8+ T cell. 3) The T cell becomes activated and travels to the tumour where it searches for 
the same antigen presented on MHC I by the tumour. 4) When the T cell finds the same 
antigen it will 5) kill the cancer cell. 
One form of antigen that DCs can take up from the tumour microenvironment 
and cross-present to naïve CD8+ T cells to start an immune response is a 
damage-associated molecular pattern (DAMP). In contrast to the PAMPs 
which are extracellular structures found on microbes, DAMPs are 
intracellular molecules that are released in the extracellular environment or 
expressed on the cell surface when the cell is stressed or injured. DAMPs are 
generally structures which during normal conditions only can be found inside 
the cell, such as RNA/DNA, the energy-carrying molecule adenosine 
triphosphate (ATP) and the calcium-binding protein calreticulin [108-110]. If 
a cell dies from non-immune related causes, it may release, for example, its 
DNA into the environment. 
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During a particular type of cell death called immunogenic cell death (ICD), 
dying cells expose and release high amounts of DAMPs, which stimulate the 
recruitment and activation of DCs and facilitate the cross-presentation to 
naïve CD8+ T cells, thus initiating an anti-tumour response [108, 109]. 
Certain chemotherapeutic agents are known to induce ICD, and this will be 
further discussed in the next section. 
1.3.3. Cancer immunology 
During recent years it has been increasingly more known that the immune 
system is important in the fight against cancer. Different immunotherapies 
boosting and regulating the immune response have successfully been applied 
to the treatment of different cancers. The academic journal Science awarded 
cancer immunotherapy the prestigious “Breakthrough of the Year” award for 
2013 [111], and the Nobel Prize in Physiology or Medicine 2018 was 
awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of 
cancer therapy by inhibition of negative immune regulation” [112]. 
1.3.3.1. Immunoediting 
Immunoediting is a balance between tumour progression and immune-
derived tumour suppression. It is a dynamic process showing how immune 
cells can both suppress and promote tumour growth, and it also shows how 
cancer cells are both negatively and positively affected by the inflammatory 
environment they reside in. Immunoediting consists of three phases, called 
the three E’s of cancer immunoediting: elimination, equilibrium and escape. 
Elimination, also known as cancer immunosurveillance, is when the immune 
system actively fights cancer cells, as previously described. During the 
elimination phase the immune system might succeed in eradicating all cancer 
cells, in which the immunoediting process finishes and does not progress to 
equilibrium. If some malignant cells survive, the process enters the 
equilibrium phase. During equilibrium the immune cells are trying to 
eradicate the remaining cancer cells, succeeding in containing them but not 
fully destroying them. This phase might persist for many years; illustrating 
that the time lag from the appearance of malignant cells to the formation of 
tumours may be very long. Due to the high selection pressure exerted by the 
immune system on the cancer cells, some cancer clones arise which are 
immunologically resistant. These clones escape the immunological attack, 
proliferate and form tumours which cannot be contained by the immune 
system. One commonly employed immune escape mechanism is the 
downregulation of MHC class I on cancer cells, thus hindering CD8+ T cells 
from recognising the cancer cells. Moreover, tumours may actively suppress 
the immune system by secreting immunosuppressive cytokines, express 
ligands to inhibitory receptors found on immune cells, and recruit 
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immunosuppressive immune cells, such as Tregs and myeloid-derived 
suppressor cells (MDSCs) [113, 114].  
1.3.3.2. Immunogenic cell death 
For a long time cell death was thought to include only apoptosis, a 
programmed and regulated non-inflammatory death, and necrosis, a non-
programmed death caused by trauma and injury and which elicits an 
inflammatory response. It is now known that there are many different types 
of regulated cell death in addition to apoptosis; all triggered by different 
events, driven by different intracellular pathways [115].  
Immunogenic cell death (ICD) is a regulated type of cell death which induces 
an immunological response. It is caused by certain chemotherapeutic drugs, 
but also by other treatments for cancers, such as radiotherapy and 
photodynamic therapy. During ICD the dying cancer cells release or express 
DAMPs which recruit and activate APCs [108, 109, 116].  
Studies have shown that exposure to melphalan causes the expression of 
some of the markers for ICD in different cancers, indicating that melphalan 
induces ICD, or at least some sort of regulated and immunogenic or 
inflammatory type of cell death. Treatment with melphalan in models of B 
cell lymphoma and colorectal cancer caused the cells to release high mobility 
group box 1 (HMGB1), an intracellular protein important for DNA 
transcription and a prototypical marker for ICD, and the upregulation of 
surface-expressed calreticulin [117]. In melanoma models exposure to 
melphalan did not cause any significant upregulation of surface-expressed 
calreticulin or release of extracellular ATP, though it did induce the 
expression of the immunogenic-related stress marker heat shock protein 90 
(Hsp90) and caused release of pro-inflammatory cytokines. Moreover, when 
immunocompetent mice were injected with dying melphalan-exposed 
melanoma cells and subsequently challenged with live non-exposed 
melanoma cells in a vaccination trial, the vaccinated mice had slower tumour 
growth. The protective effect of the vaccination was dependent on the 
presence of CD8+ T cells in the mice [118]. 
1.3.3.3. Immunotherapy 
Cancer immunotherapy includes a wide variety of different treatments which 
enhance or regulate an already existing anti-tumour immune response or 
induce an immune response if one if lacking. Immunotherapies can include 
treatment with proteins, such as cytokines and antibodies, and also the 
administration of modified and activated immune cells.  
Two examples of cytokines which are approved for the treatment of various 
cancers are IL-2 and interferons. Both are approved for the treatment of 
22 
 
advanced metastatic melanoma. To achieve durable responses during 
monotherapy high concentrations of cytokines are often needed, which cause 
severe systemic toxicities. Therefore, cytokines are more commonly being 
utilised in combination therapies rather than as monotherapies [119]. 
Monoclonal antibodies are extensively used in both treatment and research of 
cancer. There are unconjugated antibodies and conjugated antibodies, the 
latter are antibodies modified to carry other molecules, such as radioactive 
isotopes or dyes. Antibodies may act in a number of ways. They can bind 
directly to antigens on the cancer cells 
and cause death or inhibit cell growth 
through e.g. by binding to receptors or 
ligands and inhibit important 
intracellular signalling, label the 
cancer cells so that immune cells can 
find them, or deliver drugs such as 
radioactive isotopes or 
chemotherapeutic agents directly to 
the cancer cells. They can also bind to 
immune cells and regulate their 
activities, such as the highly 
successful immune checkpoint 
inhibitors which will be discussed in 
the next section. It is also possible to 
alter the tumour microenvironment 
with antibodies, for example by 
inhibiting angiogenesis [120]. 
Modified and activated immune cells have also been of interest in the 
treatment of cancer. In these kinds of treatments, the immune cells of interest 
are recovered from the patient, modified and expanded to more efficiently 
fight cancer cells, and transferred back into the patient. DC-based cancer 
vaccines are treatment options where DCs, or monocytes which can be 
converted into DCs, are extracted from the patient and cultured ex vivo. The 
immature DCs are loaded with tumour-specific antigens, such as killed 
tumour cells or tumour cell lysates, peptides or nucleic acids. They are then 
matured in culture and transferred back into the patient, aiming to induce an 
anti-tumoural T cell response. The only DC vaccine which is approved for 
clinical use today is a vaccine targeting prostate cancer [121]. 
It is also possible to directly target T cells instead of first activating DCs. In 
adoptive cell transfer (ACT) T cells are recovered from the patient, get 
heavily expanded ex vivo, and are then transferred back into the patient who 
Some antibody-related terminology: 
 
• Antibody: Protein produced by B cells 
which recognises and binds to a unique 
molecule on a pathogen. 
• Antigen: The structure on pathogens 
recognised by antibodies and the T cell 
receptor. 
• Epitope: The specific part of an 
antigen that an antibody binds to; one 
antigen may have many epitopes. 
• Monoclonal antibodies: Antibodies 
produced by one specific clone of B 
cells, recognise only one epitope on an 
antigen. 
• Polyclonal antibodies: Antibodies 
produced by many B cell clones, 
recognise the same antigen but different 
epitopes. 
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has undergone lymphodepletion to remove existing lymphocytes, thus 
removing immunosuppressive Tregs and making space for the expanded T 
cells. The T cells can be derived from resected tumours or from peripheral 
blood. Before expansion the T cells are first screened in order to identify 
clones reactive against tumour antigens, or if none can be found, the T cells 
can be genetically engineered to be tumour-specific [122]. For cutaneous 
melanoma patients it is possible to find and expand tumour-specific T cells 
directly from tumour biopsies. Cutaneous melanoma is known to be a highly 
immunogenic tumour, possibly due to melanoma being one of the forms of 
cancer harbouring the highest numbers of mutations [123]. A high mutational 
burden is correlated with a high amount of neoantigens; newly formed 
antigens negatively selected against in the thymus. Thus, a tumour with many 
neoantigens has in theory many new antigens for T cells to target.  
1.3.3.3.1 Immune checkpoint inhibitors 
The success of immune checkpoint inhibitors in the treatment of cancers, 
particular cutaneous metastatic melanoma, is one of the main reasons why the 
field of cancer immunotherapy has grown significantly during recent years.  
Immune checkpoint inhibitors can very briefly be described as antibodies 
releasing the brakes on T cells. Activated T cells need to be suppressed and 
inhibited to not cause unwanted damage. This might be achieved through the 
suppressive Tregs, but also through inhibitory receptors present on the surface 
of T cells, so called inhibitory immune checkpoints. Upon binding to their 
cognate ligands, which are often expressed on myeloid cells, the receptors 
inhibit T cell activity through different pathways. The two most known and 
targeted immune checkpoint receptors are cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), though 
many more exist and are currently being researched.  
Antibodies targeting CTLA-4 were the first immune checkpoint inhibitors to 
be developed for therapeutic purposes. CTLA-4 binds to the ligands CD80 
and CD86 on APCs, which are also ligands to the T cell receptor CD28. In 
contrast to CTLA-4 which is an inhibitory receptor, CD28 mediates 
activating signals, and the binding of CD28 on a naïve T cell to CD80 or 
CD86 on an APC is necessary for the T cell to be fully activated. CTLA-4 
and CD28 competes with each other for binding to the ligands, thus 
regulating the activation status of the T cell. CTLA-4 is expressed on Tregs; 
the competitive binding to CD80/CD86 being one of the mechanisms by 
which Tregs can suppress the function of other T cells. CTLA-4 primarily 
regulates T cells in lymph nodes or other secondary lymphoid organs, thus 
playing a part mainly during the early stages of the immune response [124, 
125]. 
24 
 
The ligands to PD-1, programmed death-ligands 1 and 2 (PD-L1, PD-L2), are 
not only expressed on myeloid cells, but can also be upregulated on cells not 
part of the immune system. They can be induced by inflammatory cytokines 
such as IFN-γ, which are produced by various immune cells upon activation, 
thus rendering the PD-1 pathway more important during an already ongoing 
immune response, in contrast to the early stage CTLA-4 pathway. Upon 
binding to its ligands, the PD-1 receptor transmits inhibitory signals, leading 
to inhibited activity and exhaustion wherein the T cell has limited 
functionality in presence of its antigen [124, 125]. The PD-1/PD-L1 axis has 
also been shown to promote the conversion of naïve CD4+ T cells and Th1 
cells into Tregs, thus contributing to an additional suppressive function of PD-
1 [126, 127]. Many tumour cells are known to express PD-L1 and PD-L2 on 
their surfaces, thus being able to themselves inhibit T cell functionality 
through the PD-1 pathway and escape anti-tumoural immune responses.  
Checkpoint inhibitors were first approved for the treatment of melanoma in 
2011, but have since then been approved for the treatment of e.g. non-small 
cell lung cancer, renal cell carcinoma and Hodgkin lymphoma [124]. In a 
large study wherein patients with stage III and IV cutaneous melanoma were 
treated with an anti-PD-1 inhibitor, an anti-CTLA-4 inhibitor or a 
combination of both, it was seen that patients treated with an anti-PD-1 agent, 
either alone or in combination with anti-CTLA-4, had a longer overall 
survival compared with patients treated with only anti-CTLA-4 inhibitors. 
Moreover, after four years approximately 50% of all patients treated with 
anti-PD-1 alone or in combination with anti-CTLA-4 were alive [128]. This 
can be compared with the five year survival rate in Sweden for stage III and 
stage IV melanoma patients which before the advent of immune checkpoint 
inhibitors were 36% respectively 25% [17].  
Despite the success of immune checkpoint inhibitors in the treatment of 
cutaneous melanoma, they have not worked as well in uveal melanoma. In 
clinical trials wherein patients with stage IV uveal melanoma were treated 
with anti-PD-1/PD-L1 antibodies alone or together with anti-CTLA-4 
antibodies, only 4-5% of all patients had a response to anti-PD-1/PD-L1 
monotherapy, while 17% responded to the combination therapy [129, 130]. 
For patients with stage III or IV cutaneous melanoma, 45% respond to anti-
PD-1 monotherapy and up to 58% respond to combination therapy [128]. 
This discrepancy between cutaneous and uveal melanoma regarding efficacy 
of immune checkpoint inhibitors implies that immune control mechanisms 
may be fundamentally different in these two diseases. 
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Figure 6. A simplified depiction of the mechanisms behind anti-PD-1 treatment. A) shows a 
CD8+ T cell attacking a cancer cell without any inhibitory mechanisms involved. In B) the T 
cell is inhibited through binding of its PD-1 receptors to PD-L1 on myeloid cells, here a DC, 
and on the cancer cell. In C) the PD-1/PD-L1 interaction is blocked through antibodies 
targeting PD-1, thus enabling the T cell to kill the cancer cell. 
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1.4. Melanoma, isolated regional perfusion, 
and immunology 
It is known that melanoma, at least cutaneous melanoma, is a very 
immunogenic tumour, as evidenced, for example, by the success of the 
immune checkpoint inhibitors. Couple that with the knowledge that some 
chemotherapeutic agents induce an anti-tumoural immune response via ICD 
and it is not hard to imagine that chemotherapy in the treatment of melanoma 
may function through two ways; via direct killing of the tumour cells and via 
induction of an anti-tumoural immune response. 
The strength of utilising isolated regional perfusion to administer 
chemotherapeutic agents is that the administration is local and not systemic. 
In addition to achieving high tissue concentrations of the chemotherapeutic 
drug, only the isolated body part should be affected by the drug, in theory 
preventing the development of systemic side effects, such as bone marrow 
suppression which leads to a decreased production of e.g. immune cells. 
While systemic chemotherapy might render the surviving cancer cells 
immunogenic, it might also wipe out the immune cells, which theoretically 
should be less of a problem during locoregional chemotherapy. 
The potential impact of the immune system on the clinical outcome to 
isolated regional perfusion with melphalan is supported by the frequently 
slow regression of melanoma tumours. It may take several months until a 
melanoma patient achieves a complete response (CR) after ILP [131], 
suggesting that the last remaining tumours are not directly killed by the 
cytotoxic effects of melphalan, but rather of an activated immune response. 
In a pilot study investigating if ILP with melphalan in the treatment of 
cutaneous metastatic melanoma induced an anti-tumoural immune response, 
it was shown that patients who achieved a CR after ILP had higher amounts 
of cytotoxic CD8+ T cells before treatment and that these patients also had 
more activated T cells [132]. These findings indicate that there might be an 
immunological component at play. If this is the case, it suggests that it might 
be beneficial to combine isolated regional perfusion with immunotherapy in 
the treatment of metastatic melanoma.  
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2. Aims 
The main objective for this thesis was to investigate the role of the immune 
system for the treatment response after isolated regional perfusion with 
melphalan in patients with metastatic melanoma. Specific aims for each paper 
are as follows: 
• Paper I and Paper II aimed to define whether or not a cellular 
immune response is induced and is of importance for the anti-
tumoural effects of isolated limb perfusion (ILP) with melphalan.  
 
• Paper III aimed at defining serum factors of relevance for the 
treatment response to ILP, in particular chemokines encoded by 
interferon-stimulated genes (ISGs). 
 
• The aim of Paper IV was to define how the composition of immune 
cells in blood and tumour of patients with uveal melanoma liver 
metastasis affected the treatment response to isolated hepatic 
perfusion (IHP) with melphalan. 
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3. Methodology 
The data presented in this thesis were generated from experiments and 
analyses of blood and tumour samples from melanoma patients treated with 
ILP and IHP, from in vivo murine vaccination models and from in vitro cell 
culture models of perfusion. 
3.1. Isolated regional perfusion 
Papers I-III contain data generated from analyses of blood samples and 
tumour biopsies from patients with cutaneous melanoma in-transit metastases 
undergoing treatment with melphalan-based ILP. PBMCs and serum were 
obtained before and after ILP, and a limited number of metastatic tumour 
biopsies were obtained during the surgical procedure. The majority of the 
patients underwent perfusion of the leg, with a few undergoing perfusion of 
the arm. All perfusions were performed at hyperthermia (40oC). 
Paper IV contains data from patients with uveal melanoma liver metastases 
treated with melphalan-based IHP. Patients were enrolled from the IHP-
treatment arm of the SCANDIUM trial, and PBMCs were collected before 
IHP from each patient. A limited number of metastatic tumour biopsies were 
obtained during the surgical procedure. 
Patients were treated at the Sahlgrenska University Hospital, with clinical 
responses evaluated at each patient’s referring hospital after three months. 
The studies were approved by the Regional Ethical Review Board in 
Gothenburg, and patients gave written informed consent before enrolment.  
3.2. In vivo murine model 
In Paper I a murine melanoma model was utilised to investigate if injection 
of melphalan-exposed dying melanoma cells into mice could function as a 
protective vaccine against tumour growth. Immunocompetent C57BL/6 mice 
were injected with B16-F1-OVA cells which had previously been pre-
exposed to sub-lethal concentrations of melphalan. The B16F1-OVA cell line 
is a murine melanoma cell line originally derived from the C57BL/6 mouse 
strain, engineered to express the chicken egg protein ovalbumin (OVA). 
Ovalbumin in itself does not cause any harm to the mice, but it does induce a 
T cell-dependent immune response [133]. As the mice have not previously 
been exposed to ovalbumin, all ovalbumin-specific immune responses 
detected in this model must originate from the reactions towards the B16F1-
OVA cells. Therefore, measurements of OVA-specific T cells may be utilised 
as a means to quantify tumour-specific T cell responses. 
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Approximately one week after injection of the cell-based vaccine the mice 
were subcutaneously injected with live B16-F1-OVA cells to generate 
tumour growth. The tumour growth was monitored, and at the end of the 
experiment all tumours were excised and analysed for immune cell 
infiltration by flow cytometry. 
The murine experiments were approved by the Animal Ethics Research 
Committee in Gothenburg. 
3.3. In vitro perfusion model 
In order to in more detail investigate the effect of a short-term exposure of 
melanoma cells to melphalan and the subsequent effects on immune cells, an 
in vitro model of isolated regional perfusion was created wherein human 
melanoma cell lines were exposed to sub-lethal concentrations of melphalan 
during one hour at hyperthermia. After the exposure the cells were 
thoroughly washed to remove the chemotherapeutic drug. PBMCs obtained 
from healthy donors were added to the melanoma cell culture for two days, 
after which supernatants were analysed for soluble factors and effects on 
myeloid cells were analysed by flow cytometry. For experiments regarding 
effects of melphalan-exposed melanoma cells on T cells, the non-adherent 
PBMCs were transferred from the melanoma cell co-culture and cultured in a 
monoculture in the presence of IL-2 for an additional four days or two weeks. 
This model was utilised in Paper I and III. 
3.4. Methods 
Different experimental methods were utilised to generate data in this study. 
The main methods were flow cytometry which was utilised for 
characterisation of immune cell phenotypes, immunoassays (Luminex-based 
multiplex assays and ELISAs) for detection of soluble factors in serum and 
cell culture supernatants), RT-qPCR for quantification of gene expression 
and immunohistochemistry for detection of immune cells in tumour biopsies. 
More detailed information about the experimental procedures can be found in 
Papers I-IV. 
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4. Results and discussion
Several different immune cell populations were investigated in the studies 
that constitute this thesis. Apparent throughout all papers was that a short-
term exposure of melanoma cells to melphalan, as during isolated regional 
perfusion, appeared to have an impact on nearby APCs, such as monocytes 
and dendritic cells, and on T cells. Moreover, it was found that melanoma 
patients harbouring immune cells of certain phenotypes showed a more 
favourable outcome after treatment with isolated regional perfusion. 
4.1. Melphalan induces an immunogenic-
type of cell death in melanoma cells 
When chemotherapeutic treatments induce ICD in cancer cells, they 
upregulate or release DAMPs which facilitate the initiation of an anti-tumour 
immune response. In Paper I we investigated if melphalan could induce ICD 
in melanoma cells. To this end, human melanoma cell lines were exposed to 
sub-lethal concentrations of melphalan, causing around 15-30% cell death, 
for one hour at 40oC to mimic the conditions for hyperthermic isolated 
regional perfusion. Approximately 24 hours after the end of the exposure the 
melanoma cells were analysed by flow cytometry in order to investigate 
whether they expressed DAMPs typically associated with ICD on their cell 
surfaces. Upon treatment with melphalan, melanoma cells upregulated the 
expression of MHC class I, heat-shock protein 70 (Hsp70) and PD-L1. Hsp70 
is an ICD-associated DAMP that promotes an anti-tumoural response through 
e.g. facilitating cross-presentation of tumour antigens by APCs and 
stimulating DC maturation [134]. MHC class I and PD-L1 are not 
prototypical DAMPs but are important in the regulation of anti-tumoural 
immune responses; expression of MHC class I is necessary for CD8+ T cells 
to recognise cancer cells, and cancer cells can upregulate the expression of 
PD-L1 to inhibit the functionality of CD8+ T cells. 
In contrast, melphalan did not cause an induction of surface-expressed 
calreticulin on melanoma cells, which is one of the major markers for ICD 
[116]. This is in line with reports from other studies [118]. When the same 
melanoma cells were exposed to sub-lethal concentrations of daunorubicin, a 
chemotherapeutic agent belonging to the class of anthracyclines which are 
known to be potent inducers of ICD [116], the cells showed a high expression 
of calreticulin, as expected during ICD.  
To further investigate the immunogenicity of melphalan-exposed melanoma 
cells, these cells were injected into immunocompetent mice to form a cancer 
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vaccine. When the mice were re-challenged with non-exposed live melanoma 
cells injected subcutaneously, the mice who had received the cell-based 
vaccine experienced reduced tumour growth (Figure 7). As a control, one 
group of mice were instead injected with melanoma cells exposed to the 
alkylating agent mitomycin C, which has shown to be a very weak inducer of 
ICD [135, 136]. In comparison to the mitomycin C-based vaccine, the 
melphalan-based vaccine was much more potent, indicating that the 
protective effects of the vaccines is not simply due to the presence of dying 
melanoma cells, and that the way in which the cells are dying matters. 
Moreover, tumours from mice vaccinated with the melphalan-based cell 
vaccine contained a higher fraction of total and of tumour-specific CD8+ T 
cells, suggesting that the protective effects of the vaccine are of an 
immunological origin. 
Even though dying melphalan-exposed melanoma cells do not express all the 
prototypical markers for ICD, they express some of them, and they provide 
protection against tumour growth in a murine vaccination model, which is 
considered to be a gold-standard method to monitor ICD [116]. Taken 
together it is apparent that melphalan causes an immunogenic or 
inflammatory type of cell death in melanoma cells. 
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Figure 7. A) Set-up for a murine vaccination model wherein immunocompetent mice were 
injected with melphalan- or mitomycin C-exposed melanoma cell or a saline control before 
being re-challenged with live non-exposed melanoma cells. At the end of the experiment when 
the first tumour reached the ethical limit (15 mm), all mice were euthanized and the tumours 
were excised. B) Mice which had been vaccinated with the melphalan-based cell vaccine were 
protected against, or experienced less, tumour growth. C) Those mice did also harbour a 
higher fraction of CD8+ T cells in their tumours. 
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4.2. Melphalan-exposed melanoma cells 
triggers induction of CD16+ monocytes and 
interferon-stimulated gene products 
In order to successfully mount an anti-tumoural T cell response, it is of 
uttermost importance to have activated and functional APCs. In Paper II we 
analysed various myeloid cell populations in peripheral blood from cutaneous 
melanoma patients treated with ILP and in vitro cell culture models of 
perfusion to investigate how a short-term exposure of melanoma cells to 
melphalan affects surrounding myeloid cells. Even though no correlation 
could be found between treatment response to ILP and percentage of different 
myeloid cell populations in peripheral blood of melanoma patients, it was 
seen that the fraction of CD16+ monocytes, but not of classical CD14++CD16- 
monocytes, increased after ILP. This was also apparent in the in vitro model 
where the presence of melphalan-exposed melanoma cells drove the 
expansion of CD16+ nonclassical monocytes. In the in vitro model there was 
also an increase in the percentage of DCs, though this could not be seen in 
blood of melanoma patients. 
As previously discussed, one important function of DCs and monocytes in 
addition to provide antigen-presentation to T cells is the production of 
cytokines. In Paper III we investigated the profile of cytokines and other 
soluble factors in serum from ILP patients and correlated them to clinical 
outcome. We saw that patients who achieved complete response (CR) after 
ILP had higher serum levels of the chemokines C-X-C motif chemokine 10 
(CXCL10) and C-C motif chemokine ligand 2 (CCL2), and of soluble PD-
L2, compared to patients who did not achieve CR (Figure 8). The levels of 
these proteins did also tend to increase after treatment. Patients who had high 
levels of all three proteins generally had a better clinical outcome than 
patients with low levels. It was seen in an in vitro model of hyperthermic 
isolated perfusion that the presence of melphalan-exposed melanoma cells 
caused a very high production of CXCL10 and CCL2 in a co-culture setting 
with PBMCs, where the presence of non-exposed melanoma cells did not 
trigger the same chemokine production. We did also investigate the serum 
level of other cytokines, such as C-C motif chemokine ligand 4 and 5 (CCL4, 
CCL5), but these chemokines did not show the same patterns as CCL2 and 
CXCL10. 
One common feature of CXCL10, CCL2 and PD-L2 is that they are all 
encoded by interferon-stimulated genes (ISGs). ISGs are genes induced by 
interferons through the intracellular JAK-STAT pathway [137] and encode 
for proteins important in the defence against virus, bacteria and other 
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pathogens. They also encode for proteins important in immune modulation 
and chemotaxis. CCL2 is mainly produced by monocytes and macrophages, 
and its expression is induced by type I and type II interferons [138, 139]. 
CXCL10 is also produced by monocytes, in addition to other cell types, but it 
is mainly induced by type II interferons [140]. 
The expression of PD-L2 has been shown to be 
stimulated by both type I and type II interferons, 
in contrast to PD-L1 which mainly is induced by 
type II [141]. The interferons themselves are 
primarily produced by e.g. DCs (the type I 
interferons) and by activated T and NK cells (the 
type II interferons) [142]. Of note, CD16+ monocytes can produce both type I 
interferons and ISG products upon stimulation [143-145].  
Type I and II interferons have been shown to be important regulators of anti-
tumoural immune responses. One explanation is that many ISGs encode for 
chemokines which recruit immune cells, such as T cells, to the tumour. In 
melanoma patients, a high level of chemokines encoded from ISGs, such as 
CXCL10, correlate with a higher infiltration of T cells [146]. It has also been 
shown that chemotherapeutic treatment with anthracyclines of various solid 
cancers causes the cancer cells to produce type I interferons which 
upregulates the expression of ISGs within the cancer cells themselves [147]. 
However, in our experiments we did not observe any induction of CXCL10 
or CCL2 production from melanoma cells following exposure to melphalan, 
which is of note not an anthracycline. 
To find a link between chemokines and tumour-infiltrating T cells, we 
correlated expression levels of CCL2 produced by cell cultures from tumour 
biopsies obtained during the ILP procedure with the amount of tumour-
infiltrating T cells from the same biopsies. We found that high CCL2 levels 
correlated with a decreased fraction of infiltrating CD4+ T cells and an 
increased fraction of CD8+ T cells among T cells within the tumours. 
Thus, a short-term exposure of melanoma cells to melphalan, as during ILP, 
drives the expansion of a subpopulation of monocytes. In addition, it also 
causes an induction of ISG products, such as chemokines, which are 
predictive for treatment response. This might be due to recruitment by the 
chemokines of cytotoxic immune cells into the tumour.  
  
Human interferons: 
 
• Type I: IFN-α, IFN-β, 
IFN-ε, IFN-κ and IFN-ω 
• Type II: IFN-γ 
• Type III: IFN-λ 
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Figure 8. A) Serum samples were obtained from cutaneous melanoma patients approximately 
the day before and one month after ILP. The expression of ISG products, such as B) CXCL10, 
C) CCL2 and D) PD-L2 were measured in all serum samples. Treatment response was 
evaluated three months after ILP, and patients who achieved CR had higher serum levels of B) 
CXCL10 before ILP and higher levels of C) CCL2 and D) PD-L2 one month after ILP. 
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4.3. Favourable outcome after ILP is 
correlated with activated and antigen-
specific T cells 
After investigating the impact of isolated regional perfusion with melphalan 
on melanoma cells and on myeloid cells, focus shifted to T cells and their 
anti-tumoural properties. It was seen in Paper I that ILP did not cause an 
expansion of either CD4+ T cells or CD8+ T cells in peripheral blood of 
cutaneous melanoma patients, as measured one month after perfusion, even 
though an in vitro co-culture model of PBMCs with melphalan-exposed 
melanoma cells drove the expansion on CD8+ T cells. In Paper II it was also 
observed that the total amount of CD8+ T cells in blood did not affect 
treatment response, even though there seemed to be a trend towards 
beneficial outcome with higher numbers of CD8+ T cells. Further analyses of 
the T cells revealed that although ILP did not affect the numbers of T cells in 
blood, it did activate them.  
HLA-DR is an MHC class II molecule which is upregulated on T cells during 
activation. T cells always express MHC class I, but expression of MHC class 
II is usually reserved for APCs. It is thought that T cells might upregulate 
HLA-DR upon activation and that they utilise it for IL-2 dependent 
proliferation [148, 149]. In Paper II we saw that patients who achieved CR 
had higher HLA-DR expression on T cells prior to ILP. Furthermore, in 
Paper I we showed that the expression of HLA-DR on both CD4+ and CD8+ 
T cells in peripheral blood of melanoma patients increased after ILP.   
Another sign indicating that ILP causes an activation of T cells is that it 
increased the expression of the chemokine receptors C-C chemokine receptor 
type 4 and 5 (CCR4, CCR5) on CD4+ T cells in peripheral blood, as observed 
in Paper III. It did also increase the expression of CCR5 and C-X-C motif 
chemokine receptor 3 (CXCR3) on NK cells, another lymphocyte with anti-
tumoural properties. These receptors are found on e.g. activated T cells and 
NK cells and are utilised during the recruitment of these cells to sites of 
inflammation or cancer. Both CCR4 and CCR5 bind to the ISG chemokines 
CCL4 and CCL5, while CCR4 also binds to CCL2. CXCR3 is the receptor 
for CXCL10. Even though we could find no correlation between the 
chemokine receptors and treatment response, the ligands to these receptors 
had an impact on treatment outcome, as seen in section 4.2. 
Using the aforementioned in vitro co-culture model with melphalan-exposed 
melanoma cell lines and PBMCs it was apparent that lymphocytes cultured 
together with melphalan-exposed melanoma cells showed a higher expression 
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of chemokine receptors and PD-1 compared to lymphocytes cultured with 
non-exposed melanoma cells. In this setting there was also an impact on 
CD8+ T cells, with upregulation of CXCR3 and CCR4, which was not seen in 
the patient material. 
Furthermore, the CD8+ T cells from the in vitro model did also show signs of 
high functionality. In Paper I we saw that CD8+ T cells from a co-culture 
with melphalan-exposed melanoma cells had very high expression levels of 
IFN-γ, granzyme B and perforin – all mediators of T cell cytotoxicity (Figure 
9). When these T cells were further cultured in a short-term culture with new 
(non-exposed) melanoma cells, they were capable of killing the melanoma 
cells.  
To further investigate the impact of melanoma-specific T cells on treatment 
response after ILP, the percentage of antigen-specific CD8+ T cells in 
peripheral blood from melanoma patients was investigated. ILP did not seem 
to cause an induction of melanoma-specific CD8+ T cells, and the presence of 
these cells did not differ between patients who achieved CR or not. 
Interestingly patients who achieved CR did harbour a higher fraction of CD8+ 
T cells specific for common viral antigens in blood before ILP, suggesting 
that activated and functional T cells are important for treatment response. The 
fact that we could not detect any differences between patients achieving CR 
or not regarding melanoma-specific CD8+ T cells might be due to e.g. 
translocation of melanoma-specific CD8+ T cells from peripheral blood into 
tumours or a to a low frequency of tumour-specific T cells in blood.  
In conclusion, a short-term exposure to melphalan, as during ILP, causes an 
activation of CD4+ and CD8+ T cell. This might lead to an increase in the 
functionality of the T cells and may recruit them to the tumour 
microenvironment.  
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Figure 9. A) A schematic diagram of an in vitro model of ILP. Cells from a human melanoma 
cell line were exposed to a sub-lethal concentration of melphalan for one hour at 40oC. The 
cells were washed and cultured in regular medium for 24 hours. PBMCs from healthy donors 
were added to the melanoma cells, and the cells were co-cultured for 48 hours. Thereafter, the 
non-adherent PBMCs were transferred to a new culture and incubated in medium with IL-2 for 
two weeks. CD8+ T cells from a co-culture with melphalan-exposed melanoma cells showed 
higher levels of B) IFN-γ, C) granzyme B and D) perforin compared to T cells cultured alone 
or in the presence of non-exposed melanoma cells.  
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4.4. Favourable outcome after IHP is 
correlated with activated T cells 
In addition to analysing samples from cutaneous melanoma patients treated 
with ILP, we did also have access to blood and tissue samples from uveal 
melanoma patients with liver metastases who were treated with IHP (Figure 
10). This material was the basis for the data presented in Paper IV. 
A comparison of peripheral blood obtained from patients before IHP and 
peripheral blood from healthy blood donors revealed that the melanoma 
patients had a different T cell profile. Melanoma patients harboured a lower 
percentage of CD8+ T cells among their PBMCs, and a higher fraction of 
Tregs. Moreover, the T cells from melanoma patients expressed higher levels 
of PD-1, however there was no difference in the other analysed activation 
marker HLA-DR.  
To investigate the impact of activated T cells on clinical outcome, we divided 
all IHP patients into two groups based on high or low expression of PD-1 or 
HLA-DR on different T cell subpopulations and looked at progression-free 
survival (PFS), e.g. the time from treatment until progression of disease, for 
each group. Patients with activated T cells, e.g. high expressions of PD-1 or 
HLA-DR, showed a longer PFS. This was especially apparent for CD4+ T 
cells where both a high expression of PD-1 and of HLA-DR was associated 
with a longer PFS. Interestingly, there was no impact of the percentages of 
the different T cell subpopulations on PFS; it was only their activation status 
that mattered. 
Even though uveal melanoma patients as a group had a lower fraction of 
CD8+ T cells in peripheral blood compared to healthy controls, further 
examination showed that it mostly was melanoma patients who did not 
respond to the IHP treatment that had low levels of CD8+ T cells. The 
responders showed levels more similar to healthy controls. This was also 
reflected in tumours, where responders had a higher degree of tumour-
infiltrating CD8+ T cells compared to non-responders. The CD8+ T cells did 
also infiltrate tumour tissue to a much higher degree than normal liver tissue.  
Thus, it seems as if activated T cells play a role for the treatment response to 
IHP as well as to ILP. Due to the low number of available tumour biopsies it 
was not possible to correlate the amount of tumour-infiltrating CD8+ T cells 
with PFS as we did for T cells in peripheral blood. However, it would have 
been a very interesting analysis to perform since it is known that a high 
degree of lymphocytic tumour-infiltration in uveal melanoma patients rather 
unexpectedly is correlated to a higher mortality; for cutaneous melanoma it is 
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the opposite [150-153]. Even though the percentage of CD8+ T cells in 
peripheral blood had no impact on survival, the finding that responders to 
IHP seem to harbour a higher amount of tumour-infiltrating CD8+ T cells in 
their metastases might indicate that the presence of tumour-infiltrating 
lymphocytes might be beneficial for uveal melanoma patients in a perfusion 
setting. 
 
Figure 10. A) Peripheral blood samples and B) tumour biopsies were obtained from uveal 
melanoma patients before IHP. PBMCs were purified from the blood and analysed by flow 
cytometry, while the biopsies were analysed by immunohistochemistry. C) Uveal melanoma 
patients harboured lower percentages of CD8+ T cells among immune cells D) than healthy 
controls. E) The tumours from the uveal melanoma patients contained a higher degree of 
CD8+-infiltration (brown staining) than F) nearby normal liver tissue within the same biopsy.  
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5. Concluding remarks 
The objective for this thesis was to investigate the role of the immune system 
for the treatment response to isolated regional perfusion with melphalan in 
patients with metastatic melanoma. Our main finding is that the treatment 
outcome following ILP and IHP partly depends on an immunological 
component, which most probably is executed through the action of cytotoxic 
CD8+ T cells. We showed that melanoma patients who harboured activated 
and antigen-specific T cells in peripheral blood prior to treatment had a better 
response and a longer progression-free survival. It was also observed that ILP 
causes an activation of T cells, together with an induction of the percentage 
of CD16+ monocytes. We did also find a melphalan-associated increased 
production of chemokines and of chemokine receptors on lymphocytes, 
which might facilitate the recruitment of the immune cells into tumours. 
These effects on the immune system might be due to a melphalan-induced 
increased immunogenicity of melanoma cells. After exposure to melphalan, 
melanoma cells expressed and upregulated DAMPs and other immune-
related stress markers, which might stimulate an immune response. Thus, 
melphalan is likely to induce an immunogenic-type of cell death in melanoma 
cells, which in turn stimulate and activate the immune system to launch an 
attack against the remaining cancer cells. 
It is important to recognise the limitations of the study and its confounding 
factors. A major factor which must be taken into consideration is the chronic 
inflammatory environment of tumours. Tumours are known to cause non-
specific chronic inflammations, which might conceal and mislead data on 
chemotherapy-induced tumour-specific immune responses. Most of the 
sample material we had access to came from peripheral blood, with a limited 
number of tumour biopsies where none was obtained after perfusion. This 
makes it more difficult to monitor tumour-specific immune responses since 
the immune profile in peripheral blood might not fully reflect the immune 
profile in tumours. It was also noted during the course of this thesis work that 
the time points for sampling might not have been optimal for all analyses. For 
the measurement of chemokines in serum it would likely have been better to 
obtain post-perfusion samples sooner after perfusion since the serum levels of 
chemokines induced by the perfusion might have declined after one month.  
In conclusion, the findings presented in this thesis indicate that the treatment 
response to ILP and IHP partially is due to the induction of an immune 
response. This proposes a potential beneficial effect of combining isolated 
regional perfusion with immunotherapy, such as immune checkpoint 
inhibitors. There is in fact a newly launched clinical trial investigating this 
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combination treatment of metastatic melanoma; the NivoILP trial 
(ClinicalTrials.gov identifier number: NCT03685890) which combines ILP 
with the neutralising anti-PD-1 antibody Nivolumab. Hopefully the addition 
of an immune checkpoint inhibitor will increase the efficacy of ILP in the 
treatment of malignant melanoma.  
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